cyrilzakka/clinical-trials huggingface dataset:
Identification of Patient Phenotypes Associated With Elevated Aldosterone Levels

Post-discharge mortality and re-hospitalization for acute heart failure (AHF) affects 15% and 30% of patients respectively, within 90 days. With over 1 million annual hospitalizations and a financial cost exceeding 20 billion dollars, AHF is a major public health burden. Yet no AHF therapy to date definitively reduces morbidity and mortality, and in stark contrast to heart attack patients, highly rated evidence in guidelines do not exist. Although AHF is a syndrome and not one disease, typical treatment of patients hospitalized with AHF suggests otherwise. Despite substantial differences among AHF patients, therapy is largely uniform; patients receive medicine to help get rid of excess volume and little else. Although decades of empirical use support the symptomatic benefits of traditional therapies, outcomes remain extremely poor. As opposed to the "one-size-fits-all" approach used unsuccessfully to date in clinical trials, identification of specific AHF patient sub-groups is critical, so that tailored therapies can be developed and tested. Preliminary data suggests that the neurohormone aldosterone may be detrimental in AHF patients. Furthermore, this hormone level appears to rise during hospitalization. The investigators therefore propose to identify specific AHF patient phenotypes associated with high serum aldosterone levels to subsequently address the hypothesis that early aldosterone blockade continued throughout hospitalization will decrease re-hospitalization and mortality. Specifically, the investigators hypothesize that AHF patients with elevated serum aldosterone levels have a distinct phenotype compared to those with lower or normal aldosterone levels. Specifically, they will be older, have a lower systolic blood pressure, lower EF, worse renal function, higher BNP, and previous hospitalization for HF.


Eligibility Criteria:
Inclusion criteria:

* Male or female ≥ 18 years of age
* AHF is the primary working diagnosis for ER management and treatment Have received or will receive IV diuretic therapy
* Enrolled within 12 hours of initial diuretic dose order

Exclusion criteria:

* Serum Cr ≥ 2.5mg/dL (males) or 2.0mg/dL (females), or eGFR \< 20 ml/min/1.73m2
* Serum potassium ≥ 5.5 mEq/L
* Transplant recipients of any kind
* Fever \> 101.0
* Severe lung disease (required home O2 or daily oral steroids)
* Acute coronary syndrome within last 30 days
* Major surgery within last 30 days
* Known hypertrophic obstructive cardiomyopathy, pericardial constriction, or hemodynamically significant valvular disease
* Life expectancy less than 12 months for any reason
* Current treatment for any malignancy of any kind
* Cardiogenic shock and/or requiring IV inotropic therapy
* Pregnant or recently pregnant within last 90 days
* Known intolerance to aldosterone antagonist
* Inability to give appropriate written consent
Evaluation of the Reliability and Usability of the Reusable "BrownieForSymphony" Pump Set

The primary objectives of this study is to evaluate how professionals rate the reliability and usability of the reusable BrownieForSymphony pump set.and the current used Symphony pump set

4.2 Secondary Objectives

The secondary objectives of this study are:

* to evaluate the rate of usability problems with the BrownieForSymphony pump set
* to evaluate the pragmatic quality (task/goal fulfilment) of the BrownieForSymphony pump set
* to evaluate first impression of lactating woman regarding pumping with the BrownieForSymphony pump set

This is a 5 day case study to evaluate the reliability and usability of the BrownieForSymphony pump set.

The study consists of two different participant groups, professionals (e.g. lactation consultants, nurses) and lactating women.

Eligibility Criteria:
Inclusion Criteria:

* Hospitalized lactating woman \>18 years which are pumping breast milk

Exclusion Criteria:

* hospitalized lactating woman has a medical indication for pumping (e.g. Mastitis, cracked nipples) lactating woman used a breast shield size \>27 and \<24
Preoperative Treatment With Noninvasive Intra-auricular Vagus Nerve Stimulation Pending Bariatric Surgery

Faced with the current obesity epidemic, new avenues of research into effective weight loss must be developed.

Among the possible actions on obesity, vagus nerve stimulation has been shown in several studies to be effective in treating epilepsy or depression, at the same time inducing weight loss in those patients. Vagus nerve stimulation has also shown to be effective on weight loss in experimental animal studies. Vagus nerve stimulation has never been attempted in obese patients awaiting bariatric surgery.

The primary objective is to demonstrate the benefit of transcutaneous vagus nerve stimulation in obese subjects awaiting surgery. Secondary objectives include, among others, the risk factors related to obesity, systemic micro-inflammation, insulin and lipid profile.

Eligibility Criteria:
Inclusion Criteria:

* Any obese patient consulting for bariatric surgery with BMI ≥ 35 and comorbidities or with BMI ≥ 40
* Consent Form signed

Exclusion Criteria:

* Permanent atrial fibrillation
* Patient on treatment that could influence measurement of Autonomic Nervus System (ANS) activity (eg. anti-arrhythmics).
* For patients previously operated (by any technique), an interval of at least 6 months since the surgery must be observed
* Pacemaker
* Serious cardiac pathology
* History of myocardial infarction
* History of Stroke
* Severe respiratory insufficiency
* Allergy in the Rhodium and in the gold
* Surgery of the vagus nerve
* Pregnant patient
If Chronic Gallbladder Diseases Increase the Incidence of PEC

This is a prospective, multi-centre trial conducts at 4 ERCP centers in China designed to determine if chronic gallbladder diseases increase the incidence of Post-Endoscopic Retrograde Choledochopancreatography-Choledocholithiasis (PEC）

Endoscopic Retrograde Choledochopancreatography(ERCP) has the advantages of less injury and faster recovery for common bile duct stone patients. However, according to our retrospective study, ERCP will has a mostly 10% possibility to get an acute purulent cholecystitis which often requires emergency intervention, when patients combined with chronic gallbladder diseases, such as chronic cholecystitis, asymptomatic gallstones, and gallbladder wall thickness, the incidence of PEC will increase accordingly. The aim of this study is to observe if chronic gallbladder disease will increase the occurence of PEC and develop a high-risk PEC model.

Eligibility Criteria:
Inclusion Criteria:

* ERCP patients with gallbladder in situ

Exclusion Criteria:

* Acute cholecystitis before surgery
* Gallbladder has been removed
* Gastrointestinal reconstruction
* Unwillingness or inability to consent for the study
* Unstable vital signs Coagulation dysfunction (INR\>1.5)
* Low peripheral blood platelet count (\<50×10 \^9 / L) or using anti-coagulation drugs
* Preoperative coexistent diseases: acute pancreatitis, GI tract hemorrhage, severe liver disease (such as decompensated liver cirrhosis, liver failure and so on), septic shock Biliary- duodenal fistula confirmed during ERCP
* Pregnant women or breastfeeding
Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT and Hib-MenC-TT or Meningitec™ in Healthy Toddlers

The purpose of this booster vaccination study is to evaluate the persistence and immune memory induced by a three-dose primary vaccination course with GSK Biologicals' MenC-TT (Neisseria meningitidis group C polysaccharide-tetanus toxoid) and GSK Biologicals' Hib-MenC-TT (Haemophilus influenzae type b-MenC-TT) or Meningitec™ vaccines in healthy toddlers aged 12-15 months by giving them a 1/5th dose of Mencevax™ ACWY.

The study is an extension of the primary vaccination study 711202/001 (MenC-TT-001). It comprises 5 groups: 4 parallel groups of toddlers vaccinated in study 711202/001 (group vaccinated with Meningitec™ is control group 1) and 1 group of naive subjects (no previous vaccination against MenC disease, control group 2). All subjects receive 1/5th dose Mencevax™ ACWY and a concomitant dose of Infanrix hexa®. 2 blood samples: prior to and 1 month after vaccination.

Eligibility Criteria:
Inclusion Criteria:

* Healthy toddlers (12-15 m) with at least 1 dose of the 3-dose vaccination course of MenC or Hib-MenC vaccine in study 711202/001, OR without previous vaccination against MenC disease but with completed primary vaccination according to the German Standing Committee on Immunization (STIKO) recommendation at least 6 months before enrolment

Exclusion Criteria:

* Previous/intercurrent booster vaccination against OR history of OR exposure to diphtheria, pertussis, tetanus, polio, hepatitis B, Hib and/or meningococcal disease.
* Planned administration/administration of a vaccine within 30 d preceding study vaccination and until study end with the exception of Infanrix hexa®.
* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
* A family history of congenital or hereditary immunodeficiency.
* History of any neurologic disorders or seizures, of allergic disease/reactions likely to be exacerbated by any component of the vaccines
OLFACTION and BIPOLAR DISODER

To compare olfactory performance between patients with BD and HC and correlate their performances to neuroimaging data


Eligibility Criteria:
Inclusion Criteria:

* Patients with BD and HC
* Fluent in french
* Having a public health insurance
* Not being on tutorship

Exclusion Criteria:

* Family history of bipolar disorder for controls
* Alcohol dependence
Genetic Information to Inform Treatment and Screening for Prostate Cancer, GIFTS Study

This trial studies the role of inherited (present at birth) mutations in cancer risk genes such as BRCA2, BRCA1, ATM, CHEK2, and others in relation to prostate cancer. This study may help researchers understand the frequency and importance of inherited mutations in cancer risk genes in patients with prostate cancer and potentially help identify better ways to treat cancer in patients who have a mutation in one of these genes.

OUTLINE:

Participants complete questionnaire over 20 minutes at baseline, then undergo collection of saliva sample for genetic testing. Participants identified to have an inherited mutation in a deoxyribonucleic acid (DNA) repair gene undergo genetic counseling. Participants whose genetic testing does not indicate an inherited mutation in a DNA repair gene receive a letter thanking them for their participation and emphasizing the importance of ongoing communication with their physician and family members about cancer risk.

Participants will be sent newsletters every year to encourage study engagement and update health questionnaires every two years.

Eligibility Criteria:
Inclusion Criteria: Case Ascertainment

* Signed informed consent form providing agreement for germline genetic testing, use and release of health and research information
* Male aged 35 to 89 years
* Diagnosis of prostate cancer
* Resident of Washington state
* Willing to complete a questionnaire (online or on paper) to provide basic demographic information, family cancer history, and health history
* Willing and able to provide a saliva sample
* United States (U.S.) mailing address

Inclusion Criteria: Family Recruitment

* Signed informed consent form providing agreement for germline genetic testing, use and release of health and research information
* Males aged 35 to 89 years
* Willingness to complete a questionnaire (online or on paper) to provide basic demographic information, family cancer history, and health history
* Willingness and ability to provide a saliva sample
* U.S. mailing address

Exclusion Criteria: Case Ascertainment

* Unable to provide informed consent, e.g. decisional impairment
* Prior bone marrow transplant
* Currently under treatment for a hematologic malignancy
* Study team members

Exclusion Criteria: Family Recruitment

* Unable to provide informed consent, e.g. decisional impairment
* Prior bone marrow transplant
* Currently under treatment for a hematologic malignancy
* Study team members
The Student Wellness and Emotional Growth Resiliency (SWAG-R) Program

The purpose of this research study is to provide a free 6-week, online psychological coaching program to NSU undergraduate students to help with anxiety, depression, and stress, while improving quality of life and healthy coping skills.

* All study participants will first complete a study pre-screen over the phone with a study team member. This screening will take 10-15 minutes.
* If participants are eligible to participate in the study, participants will be verbally guided through the Informed Consent form to determine if participants have any questions. This phone call will take approximately 10 minutes.
* Participants will then be electronically sent the Informed Consent form for participant review and to complete and sign, if participants would like to participate in the study.
* Once investigators receive the signed Informed Consent document, participants will be assigned a unique Study Identification Number and first assessment measures will be sent to complete (Time Point 1). This assessment will be completed electronically at participant convenience.
* Participants will then be randomly assigned to either start the free 6-week online coaching program OR will be randomly assigned to the waitlist for 6 weeks. Participants have an equal chance of being offered the coaching program right away or being put on the waitlist.
* The coaching program will consist of (6) free, 60 minute online coaching sessions. Participants will be assigned the same coach for the 6 weeks. Participants can coordinate schedule day/time preferences as the sessions will be done through HIPAA Zoom. Everyone in the study will get the same coaching topics in the same order.
* 6 weeks later, participants will complete another assessment (Time Point 2). This assessment will be completed electronically at participant convenience.
* If participants were on the waitlist, these participants can now start the free 6 week online coaching program, if participants would like. Participants are not obligated to participate but will be offered the program.
* If participants already completed the 6 week online coaching program, participants will not have any other coaching sessions during this time.
* 6 weeks later, participants will complete another assessment (Time Point 3). This assessment will be completed electronically at participant convenience.
* 6 weeks later, participants will complete another assessment (Time Point 4). This assessment will be completed electronically at participant convenience.

Eligibility Criteria:
Inclusion Criteria:

* Currently matriculating NSU undergraduate students (ages 18+)

Exclusion Criteria:

* Students who are not current NSU undergrads, participants aged 17 and younger, students who are currently enrolled in psychotherapy or mental health services, or students with acute mental health needs (e.g., psychosis, active alcohol or substance use problems, suicidality)
Small Intestinal Mucosal Abnormalities in Systemic Sclerosis Using Capsule Endoscopy

The aim of this prospective study is to determine prevalence and characteristics of small intestinal mucosal abnormalities in 40 patients with systemic sclerosis, using capsule endoscopy. The investigators' findings may improve management of small intestinal involvement in patients with systemic sclerosis.


Eligibility Criteria:
Inclusion Criteria:

* Written informed consent
* Systemic sclerosis based on the ACR diagnostic criteria

Exclusion Criteria:

* Patients with other connective tissue diseases
* Pregnancy
* Absence of contraception in women
* Patients with pace maker
* Patients with intestinal pseudo-obstruction
Three Instructional Interventions for Prehospital Cervical Spinal Immobilization by Laypeople

It is not known if bystanders equipped with point-of-care (POC) instruction are as effective as bystanders with in-person training for c-spine immobilization. Therefore, POC instructional interventions were developed during this study in response to the scalability challenges associated with in-person training to measure the comparative effectiveness and skill retention of POC instructions vs in-person training using a randomized clinical trial design.

Road traffic injuries (RTIs) are the largest contributor to the global injury burden, which disproportionately affects low- and middle-income countries (LMICs). Traumatic spinal cord injury (TSCI) is the highest contributor to years lived disabled (YLDs) resulting from RTIs, accounting for 74.8% of YLDs from RTI. With a lack of robust emergency medical services (EMS), there has been increasing reliance on layperson bystanders to respond to RTIs in LMICs. Early spinal immobilization has the potential to limit neurological deficits secondary to TSCI and morbidity. Bystanders may be trained in-person or point-of-care (POC) instruction may be provided, as exists with automated external defibrillators and tourniquets. However, it is unknown if bystanders equipped with POC instruction are as effective as bystanders with in-person training for c-spine immobilization. Therefore, POC instructional interventions were developed in response to the scalability challenges associated with in-person training to measure the comparative effectiveness and skill retention of POC instructions vs in-person training using a randomized clinical trial design. The POC instructional flashcard was first piloted with an initial cohort of participants who were not assigned to any longitudinal follow-up date to pilot POC instructional interventions for c-spine immobilization and receive feedback for instructional flashcard revision prior to launching the "trial." Data from these participants is not considered part of the "trial" for analytic purposes. This entire testing process is with participants who are healthy volunteers and researchers simulating spinal injury victims to test which method of instruction is most effective and durable for understanding.

Eligibility Criteria:
Inclusion Criteria:

* Understand spoken and written English.

Exclusion Criteria:

* None
Transcriptomic Profile of Endometrium in Different Histological Dating of Hormone Replacement Cycle

At present, the evaluation criterion of endometrial receptivity is controversial. The development of a molecular diagnostic tool, the endometrial receptivity array (ERA) for diagnosis of endometrial receptivity . But use of this test in patients with RIF has shown that the window of implantation (WOI) is displaced in only a quarter of these patients and use of a personalized embryo transfer (pET) on the day designated by ERA improves reproductive performance with higher cost .what is known to the others'population? The morphological changes observed on histology for each specific day after ovulation were described by Noyes and his colleagues in 1950 . An endometrial biopsy that shows a difference of more than 2 days between the histologic dating and actual day after ovulation is considered to be ''out of phase''. But such pET studies according to the Noyes criterion in hormone replacement cycle are lacking . The aim of this study is to explore the transcriptomic profile of endometrial receptivity in different histological dating of hormone replacement cycle and its clinical application.


Eligibility Criteria:
Inclusion Criteria:

* The inclusion criteria for RIF group were: unexplained repeated implantation failure (RIF) is defined as the absence of a gestational sac on ultrasound at 5 or more weeks after embryo transfer (ET) after 3 embryo transfers with high quality embryos or after the transfer of ≥10 embryos in multiple transfers.

The inclusion criteria for control group were: (1) age \<35 years; (2) unregular menstrual cycles of \>37 days; (3) baseline follicle- stimulating hormone (FSH) \< 9.0 IU/L; (4) endometrial thickness ≥7.0 mm on the day of hCG administration.

Exclusion Criteria:

* The exclusion criteria were: (1) uterine abnormalities (double uterus, bicornuate uterus, unicornuate uterus); (2) intrauterine adhesions（moderate - severe）, endometriosis, adenomyosis, untreated hydrosalpinx, uterine fibroids (submucosal fibroids, nonmucosal fibroids \>4.0 cm and/or endometrial pressure) (3) history of adverse pregnancy (including spontaneous abortion, stillbirth, and fetal malformation).
Interval Training Versus Electro Acupuncture on Liver Functions in Patients With Non-alcoholic Fatty Liver Disease

in this study, the investigators compare the effect of interval training exercise and electroacupuncture on liver functions in non-alcoholic fatty liver disease patients

fifty patients suffering from Nonalcoholic fatty liver disease (NAFLD) will be recruited in this study with age ranged from 30-55 years old from both sexes, chosen from internal medicine department at Kasr El Aini hospital and from the outpatient clinic of nutrition and cardiovascular disorders at the faculty of Physical Therapy Cairo University, they were divided in to two groups:Group (1):

Twenty-five patients suffering from Nonalcoholic fatty liver disease (NAFLD), and taking their standard medications In addition to electroacupuncture at points of LR3 (Taichong), LR14 (Qimen), GB 34(Yanglingquan) and ST36 (Zu San Li). Group (2):

Twenty-five patients suffering from Nonalcoholic fatty liver disease(NAFLD) and taking their standard medications in addition to aerobic interval training exercise.Lab investigations of:

Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Triglycerides (TG) and C-reactive protein (CRP).to judge liver functions

Eligibility Criteria:
Inclusion Criteria:

1. Sixty patients suffering from Nonalcoholic fatty liver disease (NAFLD).
2. Their age will be ranged from 30-55 years old.
3. Body mass index (30 - 40)
4. All patients are medically stable.

Exclusion Criteria:

* Patients with Hepatitis C \& b
* Acute and chronic significant illnesses that may interfere with actual training, severe ventricular arrhythmia, hemodynamic deterioration or exercise-induced arrhythmia at baseline testing.
* Co-morbidities that limit exercise tolerance (hemoglobin 10 g/dl, a chronic obstructive pulmonary disease with FEV1 50%).
* Hypertension (resting blood pressure \>140/90 mmHg).
* Heart failure, inability to exercise, or drug abuse.
* Pacemakers
* Pregnancy
* Epileptic Seizures
* Cancer